share_log

Morgan Stanley Maintains Underweight on Veracyte, Lowers Price Target to $22

Morgan Stanley Maintains Underweight on Veracyte, Lowers Price Target to $22

摩根士丹利维持对Veracyte的减持,将目标股价下调至22美元
Benzinga ·  2023/11/10 09:26

Morgan Stanley analyst Tejas Savant maintains Veracyte (NASDAQ:VCYT) with a Underweight and lowers the price target from $23 to $22.

摩根士丹利分析师Tejas Savant维持Veracyte(纳斯达克股票代码:VCYT)持有减持,并将目标股价从23美元下调至22美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发